Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe

Javed Muhammad Ahsan; Beyer Georg; Le Nha; Vinci Alessio; Wong Helen; Palmer Daniel; Morgan Robert D.; Lamarca Angela; Hubner Richard A.; Valle Juan W.; Alam Salma; Chowdhury Sumsur; Ma Yuk Ting; Archibugi Livia; Capurso Gabriele; Maisonneuve Patrick; Neesse Albrecht; Sund Malin; Schober Marvin; Krug Sebastian

首页> 外文期刊>Pancreatology: official journal of the International Association of Pancreatology (IAP) ... [et al.] >Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe

【24h】

Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe

机译：加强化疗在欧洲临床常规中转移性胰腺导管腺癌（PDAC）的影响

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Pancreatic ductal adenocarcinoma (PDAC) is associated with poor prognosis. Gemcitabine is the standard chemotherapy for patients with metastatic pancreatic adenocarcinoma (MPA). Randomized clinical trials evaluating intensified chemotherapies including FOLFIRINOX and nab-paclitaxel plus gemcitabine (NAB+GEM) have shown improvement in survival. Here, we have evaluated the efficacy of intensified chemotherapy versus gemcitabine monotherapy in real-life settings across Europe.

机译：背景：胰腺导管腺癌（PDAC）与预后差有关。吉西他滨是转移性胰腺腺癌（MPA）患者的标准化疗。评估加强化疗的随机临床试验包括Folfirinox和Nab-Paclitaxel Plus Gemcitabine（Nab + Gem）的生存改善。在这里，我们已经评估了加强化疗与吉西他滨单疗法在欧洲现实生活中的疗效。

著录项

来源
《Pancreatology: official journal of the International Association of Pancreatology (IAP) ... [et al.]》 |2019年第1期|共8页
作者
Javed Muhammad Ahsan; Beyer Georg; Le Nha; Vinci Alessio; Wong Helen; Palmer Daniel; Morgan Robert D.; Lamarca Angela; Hubner Richard A.; Valle Juan W.; Alam Salma; Chowdhury Sumsur; Ma Yuk Ting; Archibugi Livia; Capurso Gabriele; Maisonneuve Patrick; Neesse Albrecht; Sund Malin; Schober Marvin; Krug Sebastian;
展开▼
作者单位

Royal Liverpool Univ Hosp Inst Translat Med NIHR Liverpool Pancreas Biomed Res Unit Liverpool;

Univ Med Greifswald Dept Med A Greifswald Germany;

Semmelweis Univ Internal Med Dept 2 Gastroenterol Div Budapest Hungary;

Univ Pavia S Matteo Univ Hosp Fdn Dept Surg Pavia Italy;

Clatterbridge Canc Ctr NHS Fdn Trust Dept Qual &

Informat Intelligence Wirral Merseyside England;

Univ Liverpool Mol &

Clin Canc Med Liverpool Merseyside England;

Christie NHS Fdn Trust Dept Med Oncol Manchester Lancs England;

Christie NHS Fdn Trust Dept Med Oncol Manchester Lancs England;

Christie NHS Fdn Trust Dept Med Oncol Manchester Lancs England;

Christie NHS Fdn Trust Dept Med Oncol Manchester Lancs England;

New Queen Elizabeth Hosp Birmingham Dept Hepatobiliary Oncol Birmingham W Midlands England;

New Queen Elizabeth Hosp Birmingham Dept Hepatobiliary Oncol Birmingham W Midlands England;

New Queen Elizabeth Hosp Birmingham Dept Hepatobiliary Oncol Birmingham W Midlands England;

Univ Sapienza S Andrea Hosp Digest &

Liver Dis Unit Rome Italy;

Univ Sapienza S Andrea Hosp Digest &

Liver Dis Unit Rome Italy;

European Inst Oncol Div Epidemiol &

Biostat Milan Italy;

Univ Med Ctr Gottingen Dept Gastroenterol &

Gastrointestinal Oncol Gottingen Germany;

Univ Umea Dept Surg &

Perioperat Sci Umea Sweden;

Martin Luther Univ Halle Wittenberg Dept Gastroenterol &

Hepatol Halle Germany;

Martin Luther Univ Halle Wittenberg Dept Gastroenterol &

Hepatol Halle Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词
Pancreatic cancer; Intensified chemotherapy; Multicenter study;

机译：胰腺癌;加剧化疗;多中心研究;

相似文献

外文文献
中文文献
专利

1. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe [J] . Javed Muhammad Ahsan, Beyer Georg, Le Nha, Pancreatology: official journal of the International Association of Pancreatology (IAP) ... [et al.] . 2019,第1期

机译：加强化疗在欧洲临床常规中转移性胰腺导管腺癌（PDAC）的影响
2. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma (PDAC) in the ESPAC-4 Randomized Adjuvant Chemotherapy Trial [J] . Neoptolemos J. P., Jones R. P., Psarelli E. E., Pancreas . 2019,第10期

机译：ESPAC-4随机佐剂化疗试验中切除胰腺导管腺癌（PDAC）后复发模式
3. Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy [J] . Trestini Ilaria, Carbognin Luisa, Sperduti Isabella, European journal of clinical nutrition . 2018,第5期

机译：临床营养载体早期营养载体对局部晚期和转移性胰腺导管腺癌的预后影响
4. Developing a Novel Biodegradable Nanodrug Platform for Overcoming the Challenges in Treating Pancreatic Ductal Adenocarcinoma (PDAC) [C] . Saadia Nisar, Shannon Handley, Sandhya Clement Conference on Colloidal Nanoparticles for Biomedical Applications . 2021

机译：开发一种新型的可生物降解的纳米树纹平台，用于克服治疗胰腺导管腺癌（PDAC）的挑战
5. Characterization and Application of Highly Specific 2'-F RNA Aptamers Targeting a Potentially Novel Pancreatic Ductal Adenocarcinoma (PDAC) Biomarker(s). [D] . Claypool, Sarah Eileen. 2015

机译：靶向潜在的新型胰导管腺癌（PDAC）生物标记物的高特异性2'-F RNA适体的表征和应用。
6. NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice [O] . Ferdinando De Vita, Jole Ventriglia, Antonio Febbraro, 2016

机译：NAB紫杉醇和吉西他滨治疗转移性胰腺导管腺癌（PDAC）：从临床试验到临床实践
7. NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice [O] . Ferdinando De Vita, Jole Ventriglia, Antonio Febbraro, 2016

机译：NAB紫杉醇和吉西他滨治疗转移性胰腺导管腺癌（PDAC）：从临床试验到临床实践

Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe

摘要

著录项

相似文献

相关主题

期刊订阅